ST. LOUIS, Jan. 30 SAFC(R), a member of theSigma-Aldrich(TM) Group (Nasdaq: SIAL), has announced the second-phase of a$600,000 expansion of its solid-state services Pharmorphix(TM) researchfacility in Cambridge, UK, adding 7,500 sq. ft. of laboratory capacity tosupport this fast growing business within its SAFC Pharma(TM) focus area(http://www.safc-pharmorphix.com).
Solid-form characterization and research enhances understanding and allowsmodification of the physical properties of active pharmaceutical ingredients(APIs) to ensure patient benefit, optimize product development and protectintellectual property. As part of a multi-phase development program theadditional, fully refitted space is scheduled for completion in the firstquarter, 2008 and will augment the current 12,500 sq. ft. facility. Thedevelopment includes office reorganization and will facilitate installationlater this year of additional state-of-the-art spectroscopic and diffractionequipment.
SAFC Pharma Vice President of Manufacturing and European Operations,Michael Harris commented, "As new drugs and the regulatory climate continuesto become more complex, testing analysis and optimization of APIs plays anincreasingly key role in drug development. Through our Pharmorphix solid-stateresearch services SAFC Pharma is a recognized and capable player in thiscomplex field. The additional facilities reinforce our commitment to supportcustomers in niche technologies and is expected to support SAFC businessgrowth from Europe, the US and, increasingly, from Asia Pacific".
SAFC Pharma is a trusted leader for development and manufacturing ofcomplex small molecule APIs and biologic drug products. This new expansionfollows a recently announced $12 million expansion of SAFC Pharma's viralproduct manufacturing facility in Carlsbad, CA and the Pharmorphix serviceslaunch in the U.S. at its flagship high-potent manufacturing facility inMadison, WI, with new XRPD (X-ray Powder Diffraction) analytical equipment.Other recently announced investments include a $10 million expansion ofcommercial-scale APIs manufacturing and storage capacity, respectively, atArklow, Ireland and Buchs, Switzerland, a $29 million potent-fermentationexpansion in Jerusalem, Israel and a high-potent API conjugation suite at itsSt Louis, MO manufacturing campus.
About SAFC: SAFC(R) is the custom manufacturing and services group withinSigma-Aldrich that focuses on high-purity inorganics for high technologyapplications, cell culture products and services for biopharmaceuticalmanufacturing, biochemical production and the manufacturing of complex,multi-step organic synthesis of APIs and key intermediates. SAFC hasmanufacturing facilities around the world dedicated to providing manufacturingservices for companies requiring a reliable partner to produce their custommanufactured materials. SAFC has four focus areas -- SAFC Pharma(TM), SAFCSupply Solutions(R), SAFC Biosciences(TM), and SAFC Hitech(TM) -- and hadannual sales of nearly $500 million in 2006. SAFC is one of the world's 10largest fine chemical businesses. For more information about SAFC visithttp://www.safcglobal.com.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and HighTechnology company. Its biochemical and organic chemical products and kits areused in scientific and genomic research, biotechnology, pharmaceuticaldevelopment, the diagnosis of disease and as key components in pharmaceuticaland other high technology manufacturing. The Company has customers in lifescience companies, university and government institutions, hospitals, and inindustry. Over one million scientists and technologists use its products.Sigma-Aldrich operates in 36 countries and has 7,800 employees providingexcellent service worldwide. Sigma-Aldrich is committed to AcceleratingCustomer Success through Leadership in Life Science, High Technology andService. For more inf